Metabolism plays a major role in both the efficacy and safety of drugs. Screening compounds early in the drug discovery process is essential for selecting candidates with desirable drug metabolism and pharmacokinetic (DMPK) profiles.
Eurofins Pharma Discovery Services has a leading portfolio of in vitro services designed to help you understand the metabolic profile of your compound. We offer extensive phase I and phase II enzyme assays, including cytochrome P450 (CYP) inhibition and induction assays in all the major isoforms (3A4, 2D6, 2B6, 1A2, 2C8, 2C9, 2C19) and UGT phenotyping and inhibition experiments. Our metabolic stability assays measure the intrinsic clearance of your compound and we provide detailed metabolic profiling for metabolite identification as well as reactive metabolite screening using state-of-the-art Mass Spectrometry instrumentation.
Our metabolism assays are available in various test systems, including recombinant CYP’s, liver microsomes and hepatocytes from multiple species, and can be ordered individually, combined or as a selection of key services provided in our drug candidate assessment packages to provide cost savings.
We also have a variety of other drug metabolism services available including
- Compound testing for blood and plasma stability
- Glucuronide and glutathione conjugation
- Nuclear receptor activation of PXR, AhR, and CAR
- Drug transporter services in Caco-2, MDCK, membrane vesicles, and transfected cells lines
- Transporter screening for P-gp, BCRP, MRP2, BSEP, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1, MATE2-K and more
- A range of testing services to help investigate toxicities related to poor ADME PK properties
- Drug-Drug Interactions
- Lead optimization services
